환자 유래 이종이식(PDX) 모델 시장 - 세계 시장 규모, 점유율, 동향 분석, 기회, 예측 보고서(2019-2029년)

Patient-Derived Xenograft Model Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Tumor Type ; By End User ; By Region

US $ 4,850 ￦ 7,007,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,750 ￦ 8,307,000

Unprintable PDF (Group License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,775,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. Excel 파일이 제공됩니다.

한글목차

환자 유래 이종이식(PDX) 모델 세계 시장 규모 2배 이상 증가, 2029년까지 6억 5,500만 달러에 달할 전망

세계 환자 유래 이종이식(PDX) 모델 시장은 개인 맞춤형 의료에 대한 수요 증가와 암 발병률 증가로 인해 호황을 누리고 있습니다.

전략 컨설팅 및 시장 조사 전문 기업 BlueWeave Consulting은 최근 조사에서 2022년 세계 환자 유래 이종이식(PDX) 모델 시장 규모를 3억 1,256만 달러로 추산했으며, 2023-2029년 예측 기간 동안 기간 동안 환자 유래 이종이식(PDX) 모델 세계 시장 규모는 13.1%의 상당한 CAGR로 성장하여 2029년에는 6억 5,491만 달러에 달할 것으로 예측했습니다. 세계 환자 유래 이종이식(PDX) 모델 시장의 주요 성장 촉진요인으로는 암 환자 증가, 의약품 연구개발 활성화, 암 연구에 대한 공공 및 민간 부문의 지속적인 지원에 따른 맞춤형 의약품에 대한 수요 증가 등이 꼽힙니다. 미국 FDA의 우수의약품 제조 및 품질관리기준(GMP) 준수는 전임상 개발에서 매우 중요하며, Small Business Innovative Research 및 Small Business Technology Transfer Grants와 같은 정부 지원 프로그램 PDX 모델은 환자의 종양 조직을 면역결핍 동물에 직접 이식하는 것으로, 중요한 세포-세포 간 상호작용을 통해 세포를 배양하고, 면역결핍 동물에 직접 이식하여 세포-세포 간 상호작용을 유도합니다. 중요한 세포-종양 상호작용을 보존하여 전임상 약물 시험 및 바이오마커 탐색에 유용한 것으로 입증되고 있습니다. 면역결핍 쥐의 도입으로 쥐에서 PDX 모델을 쉽게 만들 수 있게 되었습니다. 연구개발 활동의 확대와 암 연구에 대한 정부 및 민간 부문의 지속적인 지원이 시장 성장의 원동력이 되고 있습니다. 그러나 높은 비용과 기술적 전문성, 윤리적 문제 등이 분석 기간 동안 전체 시장 성장을 억제할 것으로 예상됩니다.

이 보고서는 세계 환자 유래 이종이식(PDX) 모델 시장의 성장 잠재력, 향후 동향 및 통계에 대한 정보를 제공하기 위해 상세한 분석을 제공합니다. 또한 전체 시장 규모 예측을 촉진하는 요인에도 주목하고 있습니다. 이 보고서는 세계 환자 유래 이종이식(PDX) 모델 시장의 최신 기술 동향과 의사결정자가 전략적 의사결정을 내리는 데 도움이 되는 업계 인사이트를 제공할 것을 약속드립니다. 또한, 시장 성장 촉진요인, 과제, 경쟁력에 대해서도 분석합니다.

목차

제1장 조사 체계

제2장 주요 요약

제3장 세계의 환자 유래 이종이식(PDX) 모델 시장에 관한 인사이트

• 업계의 밸류체인 분석
• DROC 분석
  • 성장 촉진요인
    • 맞춤형 의료에 대한 수요 상승
    • 암 발생률 증가
  • 성장 억제요인
    • 높은 비용과 기술적 전문 지식
    • 윤리적 우려
  • 기회
    • 연구개발 확대
    • 협업과 파트너십
  • 과제
    • 모델 변동성
    • 규제상 허들
• 기술 진보/최근의 개발
• 규제 체계
• Porter's Five Forces 분석

제4장 세계의 환자 유래 이종이식(PDX) 모델 시장 개요

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 유형별
    • 마우스 모델
    • 래트 모델
  • 종양 종류별
    • 소화관 종양 모델
    • 부인과 종양 모델
    • 호흡기 종양 모델
    • 비뇨기과 종양 모델
    • 혈액 종양 모델
    • 기타
  • 최종사용자별
    • 제약 및 바이오테크놀러지 기업
    • 학술연구기관
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중남미
    • 중동 및 아프리카

제5장 북미의 환자 유래 이종이식(PDX) 모델 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 종양 종류별
  • 최종사용자별
  • 국가별
    • 미국
    • 캐나다

제6장 유럽의 환자 유래 이종이식(PDX) 모델 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 종양 종류별
  • 최종사용자별
  • 국가별
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인
    • 벨기에
    • 러시아
    • 네덜란드
    • 기타 유럽

제7장 아시아태평양의 환자 유래 이종이식(PDX) 모델 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 종양 종류별
  • 최종사용자별
  • 국가별
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주와 뉴질랜드
    • 인도네시아
    • 말레이시아
    • 싱가포르
    • 베트남
    • 기타 아시아태평양

제8장 중남미의 환자 유래 이종이식(PDX) 모델 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 종양 종류별
  • 최종사용자별
  • 국가별
    • 브라질
    • 멕시코
    • 아르헨티나
    • 페루
    • 기타 중남미

제9장 중동 및 아프리카의 환자 유래 이종이식(PDX) 모델 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 종양 종류별
  • 최종사용자별
  • 국가별
    • 사우디아라비아
    • 아랍에미리트
    • 카타르
    • 쿠웨이트
    • 남아프리카공화국
    • 나이지리아
    • 알제리
    • 기타 중동 및 아프리카

제10장 경쟁 상황

• 주요 기업과 그 제품 리스트
• 세계의 환자 유래 이종이식(PDX) 모델 시장 점유율 분석(2022년)
• 경영 파라미터에 의한 경쟁 벤치마킹
• 주요 전략적 전개(합병, 인수, 파트너십 등)

제11장 세계의 환자 유래 이종이식(PDX) 모델 시장에 대한 COVID-19의 영향

제12장 기업 개요(기업 개요, 재무 매트릭스, 경쟁 상황, 주요 인재, 주요 경쟁, 연락처 주소, 전략적 전망, SWOT 분석)

• JSR Corporation
• Wuxi Apptec
• The Jackson Laboratory
• Charles River Laboratories International, Inc.
• Taconic Biosciences, Inc.
• Oncodesign Precision Medicine
• Inotiv, Inc.
• Pharmatest Services
• Hera BioLabs
• EPO Berlin-Buch GmbH
• Xentech
• Urosphere
• Altogen Labs
• Abnova Corporation
• 기타 주요 기업

제13장 주요 전략적 추천사항

제14장 조사 방법

ksm

영문 목차

영문목차

Global Patient-Derived Xenograft (PDX) Model Market Size More Than Doubles to Touch USD 655 Million by 2029.

Global patient-derived xenograft (PDX) model market is flourishing because of the rising demand for personalized medicine and growing cancer incidence.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global patient-derived xenograft (PDX) model market size at USD 312.56 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global patient-derived xenograft (PDX) model market size to grow at a significant CAGR of 13.1% reaching a value of USD 654.91 million by 2029. Major growth drivers for the global patient-derived xenograft model market include an increasing cancer case, heightened pharmaceutical R&D, and rising demand for personalized medicines with continued support from public and private sectors for cancer research. Adherence to the US FDA Good Manufacturing Practices (GMPs) is crucial in preclinical development. Governments' initiatives, like Small Business Innovative Research and Small Business Technology Transfer Grants, offer financial support and guidance for preclinical programs. Anticipated PDX model demand is rising globally, simplifying model selection and in vivo efficacy trials. The PDX model involves direct implantation of patient tumor tissue into immune-compromised animals, preserving vital cell-tumor interactions and proving valuable in preclinical drug testing and biomarker discovery. The introduction of immunodeficient rats will facilitate PDX models in rats. Expanding R&D activities and consistent government and private sector support for cancer research drive market growth. However, high cost and technical expertise and ethical concerns are anticipated to restrain the overall market growth during the period in analysis.

Global Patient-Derived Xenograft (PDX) Model Market - Overview

The global patient-derived xenograft (PDX) model market refers to the market encompassing the use of specialized laboratory mice or other animals to implant human tumor tissues. These PDX models are created by directly transplanting cancerous tissue from a patient into an immune-deficient animal, preserving the essential interactions between human cancer cells and the surrounding microenvironment. They serve as vital tools for preclinical research in oncology, allowing scientists and researchers to study the behavior of human tumors in a more clinically relevant setting. The market includes the development, utilization, and supply of PDX models to facilitate drug testing, biomarker discovery, and co-clinical investigations in the quest for more effective cancer treatments and personalized medicine.

Impact of COVID-19 on Global Patient-derived xenograft (PDX) model Market

COVID-19 pandemic adversely affected the global patient-derived xenograft (PDX) model market. With lockdowns, restrictions on laboratory operations, and supply chain interruptions, research activities were temporarily halted or delayed. Access to resources and animal models required for PDX model development became constrained. Furthermore, prioritization of COVID-19 research led to a diversion of resources and funding. However, as the pandemic highlighted the importance of personalized medicine, it also emphasized the significance of PDX models in cancer research. As restrictions eased, the market rebounded, driven by the growing need for innovative cancer treatments and therapies.

Global Patient-Derived Xenograft (PDX) Model Market - By Tumor Type

Based on tumor type, the global patient-derived xenograft (PDX) model market is divided into Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Urological Tumor Models, and Hematological Tumor Models segments. The respiratory tumor model segment holds the highest share in the global patient derived xenograft model market by tumor type, due to the increased prevalence of respiratory cancers worldwide, leading to a heightened focus on developing models to study these tumors. Lung cancer, for instance, remains a leading cause of cancer-related deaths globally, necessitating a robust platform for research. PDX models for respiratory tumors enable researchers to closely mimic and study these cancers in vivo, facilitating the development of innovative therapies and treatment strategies. This growing demand for effective respiratory tumor models propels the segment's dominance in the global PDX model market.

Competitive Landscape

Major players operating in the global patient-derived xenograft (PDX) model market include: JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, and Abnova Corporation. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Patient-Derived Xenograft (PDX) Model Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Patient-Derived Xenograft (PDX) Model Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Patient-Derived Xenograft (PDX) Model Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Rising demand for personalized medicine
    • 3.2.1.2. Growing cancer incidence
  • 3.2.2. Restraints
    • 3.2.2.1. High cost and technical expertise
    • 3.2.2.2. Ethical concerns
  • 3.2.3. Opportunities
    • 3.2.3.1. Expansion in research and development
    • 3.2.3.2. Collaborations and partnerships
  • 3.2.4. Challenges
    • 3.2.4.1. Model variability
    • 3.2.4.2. Regulatory hurdles
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Patient-Derived Xenograft (PDX) Model Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Million)
• 4.2. Market Share and Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Mice Model
    • 4.2.1.2. Rats Model
  • 4.2.2. By Tumor Type
    • 4.2.2.1. Gastrointestinal Tumor Model
    • 4.2.2.2. Gynecological Tumor Model
    • 4.2.2.3. Respiratory Tumor Model
    • 4.2.2.4. Urological Tumor Models
    • 4.2.2.5. Hematological Tumor Models
    • 4.2.2.6. Others
  • 4.2.3. By End User
    • 4.2.3.1. Pharmaceutical & Biotechnology Companies
    • 4.2.3.2. Academic & Research Institutions
    • 4.2.3.3. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific (APAC)
    • 4.2.4.4. Latin America (LATAM)
    • 4.2.4.5. Middle East and Africa (MEA)

5. North America Patient-Derived Xenograft (PDX) Model Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Tumor Type
  • 5.2.3. By End User
  • 5.2.4. By Country
    • 5.2.4.1. United States
    • 5.2.4.1.1. By Type
    • 5.2.4.1.2. By Tumor Type
    • 5.2.4.1.3. By End User
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Type
    • 5.2.4.2.2. By Tumor Type
    • 5.2.4.2.3. By End User

6. Europe Patient-Derived Xenograft (PDX) Model Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Tumor Type
  • 6.2.3. By End User
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Type
    • 6.2.4.1.2. By Tumor Type
    • 6.2.4.1.3. By End User
    • 6.2.4.2. United Kingdom
    • 6.2.4.2.1. By Type
    • 6.2.4.2.2. By Tumor Type
    • 6.2.4.2.3. By End User
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Type
    • 6.2.4.3.2. By Tumor Type
    • 6.2.4.3.3. By End User
    • 6.2.4.4. France
    • 6.2.4.4.1. By Type
    • 6.2.4.4.2. By Tumor Type
    • 6.2.4.4.3. By End User
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Type
    • 6.2.4.5.2. By Tumor Type
    • 6.2.4.5.3. By End User
    • 6.2.4.6. Belgium
    • 6.2.4.6.1. By Type
    • 6.2.4.6.2. By Tumor Type
    • 6.2.4.6.3. By End User
    • 6.2.4.7. Russia
    • 6.2.4.7.1. By Type
    • 6.2.4.7.2. By Tumor Type
    • 6.2.4.7.3. By End User
    • 6.2.4.8. The Netherlands
    • 6.2.4.8.1. By Type
    • 6.2.4.8.2. By Tumor Type
    • 6.2.4.8.3. By End User
    • 6.2.4.9. Rest of Europe
    • 6.2.4.9.1. By Type
    • 6.2.4.9.2. By Tumor Type
    • 6.2.4.9.3. By End User

7. Asia-Pacific Patient-Derived Xenograft (PDX) Model Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Tumor Type
  • 7.2.3. By End User
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Type
    • 7.2.4.1.2. By Tumor Type
    • 7.2.4.1.3. By End User
    • 7.2.4.2. India
    • 7.2.4.2.1. By Type
    • 7.2.4.2.2. By Tumor Type
    • 7.2.4.2.3. By End User
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Type
    • 7.2.4.3.2. By Tumor Type
    • 7.2.4.3.3. By End User
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Type
    • 7.2.4.4.2. By Tumor Type
    • 7.2.4.4.3. By End User
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Type
    • 7.2.4.5.2. By Tumor Type
    • 7.2.4.5.3. By End User
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Type
    • 7.2.4.6.2. By Tumor Type
    • 7.2.4.6.3. By End User
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Type
    • 7.2.4.7.2. By Tumor Type
    • 7.2.4.7.3. By End User
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Type
    • 7.2.4.8.2. By Tumor Type
    • 7.2.4.8.3. By End User
    • 7.2.4.9. Vietnam
    • 7.2.4.9.1. By Type
    • 7.2.4.9.2. By Tumor Type
    • 7.2.4.9.3. By End User
    • 7.2.4.10. Rest of APAC
    • 7.2.4.10.1. By Type
    • 7.2.4.10.2. By Tumor Type
    • 7.2.4.10.3. By End User

8. Latin America Patient-Derived Xenograft (PDX) Model Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Tumor Type
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Type
    • 8.2.4.1.2. By Tumor Type
    • 8.2.4.1.3. By End User
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Type
    • 8.2.4.2.2. By Tumor Type
    • 8.2.4.2.3. By End User
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Type
    • 8.2.4.3.2. By Tumor Type
    • 8.2.4.3.3. By End User
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Type
    • 8.2.4.4.2. By Tumor Type
    • 8.2.4.4.3. By End User
    • 8.2.4.5. Rest of LATAM
    • 8.2.4.5.1. By Type
    • 8.2.4.5.2. By Tumor Type
    • 8.2.4.5.3. By End User

9. Middle East & Africa Patient-Derived Xenograft (PDX) Model Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Tumor Type
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Type
    • 9.2.4.1.2. By Tumor Type
    • 9.2.4.1.3. By End User
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Type
    • 9.2.4.2.2. By Tumor Type
    • 9.2.4.2.3. By End User
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Type
    • 9.2.4.3.2. By Tumor Type
    • 9.2.4.3.3. By End User
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Type
    • 9.2.4.4.2. By Tumor Type
    • 9.2.4.4.3. By End User
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Type
    • 9.2.4.5.2. By Tumor Type
    • 9.2.4.5.3. By End User
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Type
    • 9.2.4.6.2. By Tumor Type
    • 9.2.4.6.3. By End User
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Type
    • 9.2.4.7.2. By Tumor Type
    • 9.2.4.7.3. By End User
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Type
    • 9.2.4.8.2. By Tumor Type
    • 9.2.4.8.3. By End User

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Patient-Derived Xenograft (PDX) Model Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Patient-Derived Xenograft (PDX) Model Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. JSR Corporation
• 12.2. Wuxi Apptec
• 12.3. The Jackson Laboratory
• 12.4. Charles River Laboratories International, Inc.
• 12.5. Taconic Biosciences, Inc.
• 12.6. Oncodesign Precision Medicine
• 12.7. Inotiv, Inc.
• 12.8. Pharmatest Services
• 12.9. Hera BioLabs
• 12.10. EPO Berlin-Buch GmbH
• 12.11. Xentech
• 12.12. Urosphere
• 12.13. Altogen Labs
• 12.14. Abnova Corporation
• 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations

관련자료